Journal
COORDINATION CHEMISTRY REVIEWS
Volume 363, Issue -, Pages 17-28Publisher
ELSEVIER SCIENCE SA
DOI: 10.1016/j.ccr.2018.03.002
Keywords
Ruthenium(II) complexes; Supramolecular systems; Nanomaterials; Photodynamic therapy
Categories
Funding
- National Science Foundation of China [21525105, 21471164, 21778079]
- 973 Program [2015CB856301]
- Fundamental Research Funds for the Central Universities
Ask authors/readers for more resources
Despite their past triumphs, platinum-based therapeutics remain limited by chemo-resistance and severe side effects. As an alternative therapeutic modality which bypasses these issues, photodynamic therapy (PDT) holds great promise. The first FDA approved PDT agent, Photofrin, stimulated an outpouring of porphyrin-motif studies, while metallodrugs have long been underappreciated in this area. Due to their unique and versatile properties, ruthenium complexes are receiving increasing attention in the field of PDT. Herein, we introduce the recent advances in Ru(II)-based PDT agents ranging from single molecules to delicate nanomaterials, how these agents are unique suited to PDT and the merits provided by their various forms. (C) 2018 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available